Arrowhead Pharmaceuticals, Inc. (ARWR) Financial Statements
Arrowhead Pharmaceuticals, Inc. (ARWR) reported trailing twelve-month revenue of $669.5M (up 16.8% year on year) and net income of -$320.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$75.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ARWRArrowhead Pharmaceuticals, Inc.Follow ARWR — free
—
Price chart with a free account
- Market cap
- 8.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 23 Nov, in 29 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Sep 11 | FY2012 Sep 12 | FY2013 Sep 13 | FY2014 Sep 14 | FY2015 Sep 15 | FY2016 Sep 16 | FY2017 Sep 17 | FY2018 Sep 18 | FY2019 Sep 19 | FY2020 Sep 20 | FY2021 Sep 21 | FY2022 Sep 22 | FY2023 Sep 23 | FY2024 Sep 24 | FY2025 Sep 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | 0.17 | 0.09 | 0.14 | 0.24 | 0.24 | 0.00 | 0.83 | 0.67 | |
| Gross profit | — | — | — | — | — | — | — | — | 0.09 | — | — | — | — | — | — | — | |
| Research & development | 0.00 | 0.01 | 0.01 | 0.02 | 0.05 | 0.06 | 0.05 | 0.05 | 0.08 | 0.13 | 0.21 | 0.30 | 0.35 | 0.51 | 0.61 | 0.72 | |
| Operating income | -0.01 | -0.02 | -0.02 | -0.05 | -0.10 | -0.08 | -0.04 | -0.06 | 0.06 | -0.09 | -0.15 | -0.18 | -0.21 | -0.60 | 0.10 | -0.23 | |
| Pre-tax income | -0.01 | -0.02 | -0.03 | -0.06 | -0.09 | -0.08 | -0.03 | -0.05 | 0.07 | -0.08 | -0.14 | -0.17 | -0.21 | -0.61 | 0.05 | -0.25 | |
| Income tax | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.02 | 0.02 | |
| Net income | -0.00 | -0.02 | -0.03 | -0.06 | -0.09 | -0.08 | -0.03 | -0.05 | 0.07 | -0.08 | -0.14 | -0.18 | -0.21 | -0.60 | -0.00 | -0.32 | |
| Diluted EPS ($) | -0.40 | — | -1.30 | -1.25 | -1.60 | -1.34 | -0.47 | -0.65 | 0.69 | -0.84 | -1.36 | -1.67 | -1.92 | -5.00 | -0.01 | -2.25 | |
| Diluted shares (bn) | 0.008 | — | — | — | — | — | 0.074 | 0.084 | 0.099 | 0.101 | 0.104 | 0.105 | 0.107 | 0.120 | 0.134 | — |
USD billions · SEC XBRL
Arrowhead Pharmaceuticals, Inc. — questions
- What is Arrowhead Pharmaceuticals, Inc.'s revenue?
- $669.5M over the twelve months to 2026-06-30, up 16.8% year on year, from its 10-Q and 10-K filings.
- What is Arrowhead Pharmaceuticals, Inc.'s net income?
- -$320.0M over the twelve months to 2026-06-30.
- What is Arrowhead Pharmaceuticals, Inc.'s free cash flow?
- -$75.1M over the twelve months to 2026-06-30.
- What are Arrowhead Pharmaceuticals, Inc.'s diluted earnings per share?
- $-2.25 over the twelve months to 2026-06-30.
Every figure on this page comes from Arrowhead Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.